Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

WOK vs SGHT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SGHT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–1 Matrix Metrics)

SGHT Overall Winner 6-Pillar Tally: WOK 2 – 4 SGHT Matrix Metrics: WOK 1 – 7 SGHT

As of Nov 16, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). WOK carries a Unified Composite Score of 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin), whereas SGHT carries 35.1/100 (SELL) at $10.59 (N/M Forward P/E, -20.2% operating margin).

  • Defensive Composite Rating Caution: Although SGHT compares more favorably head-to-head, both WOK (25.6/100 SELL) and SGHT (35.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About WOK vs SGHT
WOK NASDAQ
WORK Medical Technology Group LTD Class A Ordinary Shares
Surgical & Medical Instruments & Apparatus
$1.23
+2.5% 1D
Market Cap $5.4M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 38.49β · 153% Vol
Unified Composite Score
25.6 / 100 SELL
Tech 5.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.1 · SMA20: $1.13 · SMA50: $1.47
SGHT NASDAQ Head-to-Head Winner
Sight Sciences, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$10.59
-2.22% 1D
Market Cap $601.9M
TTM Revenue $88M
Forward P/E N/M
Beta / 30D Vol 1.05β · 45% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 50.0 Fund 32.0 Flow 57.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.0% over 20 days), RSI 64
RSI-14: 64.1 · SMA20: $9.74 · SMA50: $9.01

6-Pillar Scorecard Institutional Category Breakdown (WOK 2 – 4 SGHT)

Columns: Metric · WOK · SGHT
1. Valuation Multiples WOK
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.5x 6.4x
2. Growth & Scale SGHT
Revenue Growth (YoY) +19.1% +25.2%
Earnings Growth (YoY) -95.0% +0.0%
TTM Revenue (USD) $11M $88M
Market Cap $5.4M $601.9M
3. Profitability & Quality SGHT
Gross Margin 17.0% 87.7%
Operating Margin -41.7% -20.2%
Net Profit Margin -41.9% -32.1%
Return on Equity (ROE) -19.2% -50.1%
4. Balance Sheet & Cash Flow SGHT
Cash Generation (TTM) -$3.4M EBITDA -$17M
Cash Flow Margin -31.4% EBITDA Mgn -19.1%
Net Cash / Leverage $1855.16 Book/Sh · -19.2% ROE $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGHT
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile N/A (N/A) 78.7% (8th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat WOK
OpEx & R&D Intensity 58.7% of Rev ($6.3M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: WOK (1) vs SGHT (7)
Institutional Metric WOK SGHT Criterion Row Edge
Market Capitalization
Scale
$5.4M $601.9M Larger Scale SGHT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+19.1% +25.2% Higher Growth SGHT
Operating Margin (TTM)
Profitability
-41.7% -20.2% Higher Margin SGHT
Net Profit Margin
Profitability
-41.9% -32.1% Higher Margin SGHT
Return on Equity (ROE)
Capital Efficiency
-19.2% -50.1% Higher ROE WOK
52-Week Range Position
Momentum
16% ($0–$7) 88% ($3–$12) Stronger Trend SGHT
Beta / 30D Volatility
Risk Regime
38.49β · 153% Vol 1.05β · 45% Vol Lower Realized Risk SGHT
Unified Institutional Score
Composite Signal
25.6 / 100 (SELL) 35.1 / 100 (SELL) Higher Composite SGHT
Trailing 12M Revenue (USD)
Operating Scale
$11M $88M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
17.0% 87.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.5x EV/Rev N/M PEG · 6.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.4M EBITDA ($1855.16 Book/Sh · -19.2% ROE) -$17M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGHT +15.06 pp
WOK: +12.84% · SGHT: +27.9%
3M Horizon SGHT +72.92 pp
WOK: -44.09% · SGHT: +28.83%
6M Horizon WOK +105.78 pp
WOK: +223.68% · SGHT: +117.9%
1Y Horizon SGHT +122.26 pp
WOK: -72.05% · SGHT: +50.21%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on WOK vs SGHT. Trailing 12-month operating profitability (WOK -41.7% vs SGHT -20.2%) and valuation multiples (WOK N/M vs SGHT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

WOK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross Margin17.0%
Op. Margin-41.7%
ROE / Fwd P/E-19.2% · N/M
SGHT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$88M
Gross Margin87.7%
Op. Margin-20.2%
ROE / Fwd P/E-50.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
WOK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WOK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGHT BREAKOUT
33d in phase · OBV ACCUMULATION
Current IV 78.7%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SGHT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
WOK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $5.4M market capitalization and -41.7% operating margin.
OpEx & R&D Reinvestment 58.7% of Rev ($6.3M)
90D Engineering Disclosures 0 Published
SGHT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $601.9M market capitalization and -20.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ WOK vs SGHT Key Questions & Quantitative Answers

As of Nov 16, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). WOK carries a Unified Composite Score of 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin), whereas SGHT carries 35.1/100 (SELL) at $10.59 (N/M Forward P/E, -20.2% operating margin). Defensive Composite Rating Caution: Although SGHT compares more favorably head-to-head, both WOK (25.6/100 SELL) and SGHT (35.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

SGHT leads the Growth & Scale pillar: WOK posts +19.1% YoY revenue growth and -95.0% YoY earnings growth on $11M TTM revenue (17.0% gross margin, -41.7% operating margin), compared with SGHT at +25.2% YoY revenue growth and +0.0% YoY earnings growth on $88M TTM revenue (87.7% gross margin, -20.2% operating margin). On trailing 12-month operating scale, WOK generates $11M in USD-normalized revenue versus $88M for SGHT. In operating R&D and SG&A reinvestment, WOK deploys 58.7% of Rev ($6.3M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGHT.

WOK screens cheaper on headline valuation multiples. WOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-31.4% EBITDA margin), whereas SGHT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-19.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WOK (-19.2% ROE) versus SGHT (-50.1% ROE) capital efficiency.

In options market volatility and institutional positioning, WOK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (38.49β · 153% Vol realized risk). By comparison, SGHT carries 78.7% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.05β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

WORK Medical Technology Group LTD Class A Ordinary Shares (WOK) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.